Regeneron Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Regeneron Pharmaceuticals hat ein Gesamteigenkapital von $27.0B und eine Gesamtverschuldung von $2.0B, wodurch sich der Verschuldungsgrad auf 7.3% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $34.4B bzw. $7.4B. Regeneron Pharmaceuticals Das EBIT des Unternehmens beträgt $4.0B, so dass der Zinsdeckungsgrad -8.1 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $10.5B.

Wichtige Informationen

7.0%

Verhältnis von Schulden zu Eigenkapital

US$1.98b

Verschuldung

Zinsdeckungsgrad	-7.3x
Bargeld	US$9.81b
Eigenkapital	US$28.21b
Gesamtverbindlichkeiten	US$7.88b
Gesamtvermögen	US$36.09b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Oct 25

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Oct 25

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: REGNDie kurzfristigen Aktiva des Unternehmens ($18.9B) übersteigen seine kurzfristigen Passiva ($3.6B).

Langfristige Verbindlichkeiten: REGNDie kurzfristigen Vermögenswerte des Unternehmens ($18.9B) übersteigen seine langfristigen Verbindlichkeiten ($3.8B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: REGN über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: REGNDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 7.3% gestiegen.

Schuldendeckung: REGNDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (238.9%).

Zinsdeckung: REGN mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

Regeneron Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Executive VP exercised options and sold US$5.6m worth of stock

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Co-Founder exercised options and sold US$1.0m worth of stock

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Co-Founder exercised options and sold US$104m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Co-Founder exercised options and sold US$68m worth of stock

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider exercised options and sold US$14m worth of stock

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Independent Director notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Senior VP notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Executive Vice President of Research exercised options and sold US$11m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen